Title: Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease
Authors: Jurgens, Matthias ×
John, Jestinah M. Mahachie
Cleynen, Isabelle
Schnitzler, Fabian
Fidder, Herma
Van Moerkercke, Wouter
Ballet, Vera
Noman, Maja
Hoffman, Ilse
Van Assche, Gert
Rutgeerts, Paul J
Van Steen, Kristel
Vermeire, Severine #
Issue Date: May-2011
Publisher: W.B. Saunders for the American Gastroenterological Association
Series Title: Clinical Gastroenterology and Hepatology vol:9 issue:5 pages:421-U1420
Abstract: BACKGROUND & AIMS: Infliximab is an antibody against tumor necrosis factor-alpha that is used to treat patients with moderate to severe Crohn's disease (CD). C-reactive protein (CRP) is a marker used to identify and follow individuals with CD. We analyzed changes in levels of CRP in a large cohort of patients with CD undergoing treatment with infliximab. METHODS: Serial levels of CRP were analyzed in 718 CD patients. Blood was collected before each infusion; a total of 8845 CRP levels were available for analysis. The correlations between CRP levels and need for dose adjustment, outcomes, and mucosal healing (based on endoscopic analysis of 253 patients) were evaluated. Therapy adjustment was considered successful if therapy continued without need for change. Subgroup analysis was performed by using data from 268 patients who received 8 weeks of maintenance therapy. RESULTS: More patients with high baseline levels of CRP responded to infliximab than patients with normal levels (90.8% vs 82.6%; P = .014). Early normalization of CRP levels correlated with sustained long-term response (P < .001). CRP levels remained significantly higher among patients who lost their response to infliximab, compared with those with a sustained response (P = .001). At time of loss of response, CRP levels were significantly increased (median, 11.2 mg/L) and did not return to baseline levels (median, 18.2 mg/L; P = .039). CRP correlated with mucosal healing (P = .033). CONCLUSIONS: CRP is a good marker of disease activity in patients treated with infliximab. Increased levels of CRP indicate mucosal inflammation and a likelihood of clinical relapse.
ISSN: 1542-3565
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Translational Research in GastroIntestinal Disorders
Laboratory of Pediatric Immunology
Department of Human Genetics - miscellaneous
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
Jurgens Clin Gastroenterol Hepatol 2011.pdfpublisher's version pdf Published 1526KbAdobe PDFView/Open Request a copy

These files are only available to some KU Leuven Association staff members


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science